Disease Landscape and Forecast Insights

Acute heart failure (AHF) is one of the leading causes of hospitalization in the United States, representing a significant healthcare burden. AHF patients experience high rates of mortality and…

First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, oral beta blocker, and oral diuretic. Second- or third-line treatments is…

From disease basics to insightful analysis of market dynamics, Heart Failure | Disease Landscape & Forecast | G7 provides comprehensive disease coverage addressing critical aspects of the heart…

One of the most intriguing but administratively difficult trends in U.S. health insurers’ attempts to control the rising costs of prescription drugs is the use of outcomes-based contracting,…

The chronic heart failure therapy market is crowded and dominated by generics. In 2015 in the United States, the first new branded agents in more than 15 years entered that market. Using primary…

Despite advances in treatment, rates of mortality and hospitalization for worsening heart failure remain high among CHF patients, and development of therapies with improved efficacy is one of the…

Chronic heart failure patients are subject to high rates of mortality and morbidity and frequent readmissions to the hospital mean that chronic heart failure also represents a significant…

Chronic heart failure (CHF) describes the long-term management of heart failure outside of the hospital setting. The disease progression of CHF is a gradual process that is heavily influenced by…

How Are Novel Therapies Differentiated from Current Treatment Options in This Highly Genericized Market? Acute heart failure (AHF) is one of the leading causes of hospitalization in the…

Heart failure describes a pathophysiological state in which the heart is unable to efficiently supply the body with oxygenated blood in order to meet the body’s metabolic demands. While acute…

The number of diagnosed acute heart failure (AHF) events and prevalent chronic heart failure (CHF) cases in the seven major markets that we cover is increasing annually, driven by changes in the…

In the Era of Generic Cardiovascular Agents, Can Emerging Therapies Achieve Substantial Clinical Differentiation to Gain Widespread Use? Chronic heart failure (CHF) describes the long-term…